1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

Adenosine deaminase deficiency

  1. Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease.
  2. ADAR1 is required for hematopoietic progenitor cell survival via RNA editing.
  3. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
  4. [Late onset of primary immune deficiencies]
  5. RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment.
  6. Pediatric neurological syndromes and inborn errors of purine metabolism.
  7. Determination of adenosine deaminase activity in dried blood spots by a nonradiochemical assay using reversed-phase high-performance liquid chromatography.
  8. Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death.
  9. Ten years of gene therapy for primary immune deficiencies.
  10. [Gene therapy for severe combined immunodeficiency]
  11. Primary immunodeficiencies (PIDs) presenting with cytopenias.
  12. Update on gene therapy for immunodeficiencies.
  13. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
  14. Gene therapy for adenosine deaminase deficiency.
  15. Late-onset adenosine deaminase deficiency presenting with Heck's disease.
  16. 20 years of gene therapy for SCID.
  17. [New roles of glutamate receptors in glias and gliomas]
  18. A novel mutation in the ADA gene causing severe combined immunodeficiency in an Arab patient: a case report.
  19. New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy.
  20. Progress and prospects: gene therapy for inherited immunodeficiencies.